The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder
ID Number 10-1060Principal Investigator(s)
Dan V Iosifescu
Department(s) or Division(s)
This research study is evaluating a medication that helps with memory in patients with bipolar disorder. This research study examines the effectiveness of galantamine compared to placebo (contains no active medication) in the treatment of bipolar patients who complain of everyday memory or attention difficulties. Galantamine is a medication that is currently approved by the FDA for the treatment of Alzheimer's Disease, but may prove effective in treating cognitive difficulties in patients with bipolar disorder as well. In this study, patients will receive either galantamine or placebo for 4 months at no cost. Participation in this research study is expected to last 18 weeks, and includes six outpatient visits. Participants will be reimbursed for their time. Volunteers may be eligible for this study if they are between the ages of 18 and 65 and have a diagnosis of bipolar disorder, and are currently not experiencing a mood episode of depression or mania.
Recruiting Patients: No